Literature DB >> 12531081

Basic epidemiology and immunopathology of RSV in children.

J Handforth1, J S Friedland, M Sharland.   

Abstract

Respiratory syncytial virus (RSV) is the most important cause of lower respiratory tract infection in infants and young children. Around 20 000 RSV-infected infants require hospitalization in the UK during each yearly epidemic, which is about 3% of the birth cohort. Most children are infected by 2 years of age. Risk factors for severe disease include young infants, prematurity, chronic lung and cardiac conditions or immunodeficiency. Humoral immunity is incomplete and short-lived, yet reinfections cause less severe disease. RSV infects infants despite the presence of specific neutralizing antibodies. RSV infection can be linked to the development of individual wheezing episodes. A competent cellular immune system is necessary to reduce disease severity. RSV infection provokes an RSV-specific T-lymphocyte response with the release of cytokines. There is a delicate balance between the protective and disease-enhancing effects of the host's immune response to RSV infection.

Entities:  

Mesh:

Year:  2000        PMID: 12531081     DOI: 10.1053/prrv.2000.0050

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  13 in total

1.  Prevention of respiratory syncytial virus infection in infants.

Authors:  Jenny Handforth; Mike Sharland; Jon S Friedland
Journal:  BMJ       Date:  2004-05-01

2.  Respiratory syncytial virus (RSV) infects neuronal cells and processes that innervate the lung by a process involving RSV G protein.

Authors:  Xia-qing Li; Zhen F Fu; Rene Alvarez; Christine Henderson; Ralph A Tripp
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Reversion of somatic mutations of the respiratory syncytial virus-specific human monoclonal antibody Fab19 reveal a direct relationship between association rate and neutralizing potency.

Authors:  John T Bates; Christopher J Keefer; Thomas J Utley; Bruno E Correia; William R Schief; James E Crowe
Journal:  J Immunol       Date:  2013-03-01       Impact factor: 5.422

Review 4.  Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age.

Authors:  X Carbonell-Estrany; L Bont; G Doering; J-B Gouyon; M Lanari
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-16       Impact factor: 3.267

Review 5.  The host response and molecular pathogenesis associated with respiratory syncytial virus infection.

Authors:  Christine M Oshansky; Wenliang Zhang; Elizabeth Moore; Ralph A Tripp
Journal:  Future Microbiol       Date:  2009-04       Impact factor: 3.165

Review 6.  Surfactant therapy for bronchiolitis in critically ill infants.

Authors:  Kana R Jat; Deepak Chawla
Journal:  Cochrane Database Syst Rev       Date:  2015-08-24

7.  Age related changes in T cell mediated immune response and effector memory to Respiratory Syncytial Virus (RSV) in healthy subjects.

Authors:  Maria Grazia Cusi; Barbara Martorelli; Giuseppa Di Genova; Chiara Terrosi; Giuseppe Campoccia; Pierpaolo Correale
Journal:  Immun Ageing       Date:  2010-10-20       Impact factor: 6.400

8.  Simulation of four respiratory viruses and inference of epidemiological parameters.

Authors:  Julia Reis; Jeffrey Shaman
Journal:  Infect Dis Model       Date:  2018-03-19

9.  HLA-associated susceptibility to childhood B-cell precursor ALL: definition and role of HLA-DPB1 supertypes.

Authors:  G M Taylor; A Hussain; T J Lightfoot; J M Birch; T O B Eden; M F Greaves
Journal:  Br J Cancer       Date:  2008-03-11       Impact factor: 7.640

10.  Effectiveness of 3% hypertonic saline nebulization in acute bronchiolitis among Indian children: A quasi-experimental study.

Authors:  Harsh V Gupta; Vivek V Gupta; Gurmeet Kaur; Amitoz S Baidwan; Pardeep P George; Jay C Shah; Kushal Shinde; Ruku Malik; Neha Chitkara; Krushnan V Bajaj
Journal:  Perspect Clin Res       Date:  2016 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.